Polaryx Therapeutics Inc. Common Stock

PLYX | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.78

+$0.03 (+1.71%)

Nov 2, 2026, 9:45 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.71%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

37.7

+14.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #584/1028 (Top 57%)

Full Analysis

Key Statistics

Market Data

Market Cap $88.73M

1D Range

1.73 1.78

52W Range

1.73 35.00

Valuation (TTM)

PE -14.58

PB 7.97

EV/EBITDA -11.05

Valuation (NTM)

Forward PE N/A

Forward PEG -0.44

Price Target $6.50

Cash Flow

FCF Yield -6.7%

SBC Adj. FCF Yield -7.3%

SBC Impact -9.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -58.0%

ROE -117.6%

ROIC -47.8%

Financial Health

Net Cash

$11.54M

Current Ratio 13.53

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes...

Sector Healthcare

Industry Biotechnology

Employees 11

IPO Date Feb 2, 2026

Website polaryx.com

Fiscal Year January - December

Full Company Profile

Latest News

9 months ago · globenewswire.com

Polaryx Therapeutics Welcomes New Members of the Board of Directors

PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announces the appointments of Mitchel Berger, M.D., Francis A.